anaplastic lymphoma kinase


Also found in: Acronyms.

anaplastic lymphoma kinase

A member of the insulin receptor subfamily of receptor tyrosine kinases, which acquires transforming capability when truncated and fused to nucleophosmin in the t(2;5) chromosomal rearrangement, resulting in the NPM-ALK chimeric protein associated with NHL.

Normal expression
Small intestine, testis, brain.
References in periodicals archive ?
18) Anaplastic lymphoma kinase IHC can elucidate the true ALK status of borderline FISH findings and the combined use with FISH can improve the accuracy of ALK screening.
Based on the presence or absence of aberrant expression of the anaplastic lymphoma kinase (ALK) gene located on chromosome 2, two forms of ALCL are recognized.
Ensartinib (X-396) is a potent anaplastic lymphoma kinase inhibitor currently in a global Phase 3 trial in ALK positive non-small cell lung cancer patients.
ALK+, CD30-, CD20- large B-cell lymphoma containing anaplastic lymphoma kinase (ALK) fused to clathrin heavy chain gene (CLTC).
Buller, Vice President of Oncology, Clinical Development & Head of Global Product Development at Pfizer will give a keynote presentation on, "Feedback Loops Between Biomarkers and Targeted Agents in Clinical Trials and Beyond: Lessons from Anaplastic Lymphoma Kinase (ALK+) Driven Non-Small Cell Lung Cancer (NSCLC)" at GTCbio's Biomarker Summit Europe 2016 to be held on October 5-7, 2016 in Berlin, Germany.
The most prevalent oncogenic alterations include the epidermal growth factor receptor mutations, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations, anaplastic lymphoma kinase rearrangement (ALK-EML4) and KIF5B-RET translocations.
Anaplastic lymphoma kinase (ALK) is a tyrosine kinase receptor that is expressed in 60%-85% of ALCLs, but rarely in PCALCL, Dr.
ALCL is a rare disease, comprising approximately 3% of adult non-Hodgkin's lymphomas (5)and is often associated with genetic alterations involving the anaplastic lymphoma kinase (ALK) locus on chromosome 2 (6).
Most notably, Pfizer's first-in-class crizotinib, a TKI targeting anaplastic lymphoma kinase (ALK) and hepatocyte growth factor receptor tyrosine kinase (HGFR)/human mesenchymal-epithelial transition factor (c-MET) has proven extremely efficacious in the small population of NSCLC patients who express the echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion protein.
The US Food and Drug Administration has approved South San Francisco, California-based biotechnology company Genentech's supplemental New Drug Application for Alecensa (alectinib) for the treatment of people with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test, the company said.
The company said the expanded use of Zykadia (ceritinib) will include the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours are anaplastic lymphoma kinase (ALK)-positive, as detected by an USD FDA-approved test.